Verrica Pharmaceuticals Inc. (VRCA) Debt / Equity
- 2025-12-31: Debt/Equity Ratio 0.
- 2025-09-30: Debt/Equity Ratio -2.
- 2025-06-30: Debt/Equity Ratio -2.13.
- 2025-03-31: Debt/Equity Ratio -2.19.
Complete source-backed debt/equity ratio history.
- Available history
- 2022-12-31 to 2025-12-31
- Data captured
Historical Debt/Equity Ratio
| Date | Debt/Equity Ratio |
|---|---|
| 2025-12-31 | 0 |
| 2025-09-30 | -2 |
| 2025-06-30 | -2.13 |
| 2025-03-31 | -2.19 |
| 2024-12-31 | -4.45 |
| 2023-12-31 | 2.17 |
| 2022-12-31 | 0 |
Annual Debt/Equity Ratio
| Date | Debt/Equity Ratio |
|---|---|
| 2025-12-31 | 0 |
| 2024-12-31 | -4.45 |
| 2023-12-31 | 2.17 |
| 2022-12-31 | 0 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |